Drugs / TRI-611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07491497 | Mar 2026 → May 2029 expected | non-small cell lung carcinoma | TRIANA Biomedicines, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRI-611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07491497 ↗ |
| Route | Oral | “oral ALK molecular glue degrader” NCT07491497 ↗ |
| Target | ALK | “oral ALK molecular glue degrader” NCT07491497 ↗ |